T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals

  • ID: 3723335
  • Report
  • Region: Global
  • 230 Pages
  • La Merie Publishing
1 of 4
Despite Stunning Clinical Results with CD19-targeted CAR T-cells, Many Major Pharmaceutical Companies have not Embarked on this Field of Adoptive Cell Therapy

FEATURED COMPANIES

  • Adimab
  • Bayer
  • Eureka Therapeutics
  • ImmuneXcite
  • Molecular Partners
  • Regeneron Pharmaceuticals
  • MORE
Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR).

Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on this field of adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.

Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development. Within 18 months, the number of clinical stage T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months.

This report "T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals" as of May 2016 brings you up-to-date information about and analysis of 34 corporate players, 22 key technologies, 47 T-cell and NK-cell redirecting bispecific antibody profiles, business deals and private and public financing rounds.

The report analyzes the pipeline of T-cell and NK-cell redirecting bispecific antibody molecules regarding preferred targets, molecular constructs, dosing schedules, clinical experience, combination study plans, competition with other treatment modalities and the next wave of T-cell and NK-cell redirecting antibodies.

Preferences in bispecific antibody technologies are evaluated regarding drug candidate output, partnering, technological features and impact on clinical administration regimens.

The report highlights the commercial value of T-cell redirecting bispecific antibody immunotherautics in terms of drug prices, sales, company acquisition prices, economic terms of partnering deals, and private or public financing rounds.

All information in the report is fully referenced with 159 scientific references, in many cases with hyperlinks leading to the source of information (abstracts, Posters, papers). Non-scientific references, such as press releases, annual reports or company presentations are disclosed within the text with an embedded hyperlink leading to the online source of information.

What will you find in the report?

- Profiles of 34 companies active in the field;
- Comprehensive description of 23 established and emerging T-cell or NK-cell redirecting antibodies
- Profiles of two approved and 45 T-cell or NK-cell redirecting bispecific antibodies in all phases of development;
- Technology selection and preferences of major pharma;
- Key characteristics of technologies with clinical stage drug candidates
- Emerging alternative bi- and trispecific formats
- Target selection and competition in drug candidates
- Competition of recombinant bispecific molecules with alternative treatment modalities
- Dosing schedules of clinical stage drug candidates based on molecular features
- Economic terms of collaboration and licensing deals;

Who will benefit from the report?

- Venture capital, private equity and investment managers;
- Financial analysts;
- CFO;
- Business development and licensing (BDL) specialists;
- Marketing managers;
- CEO, COO and managing directors;
- Corporate strategy, product and portfolio analysts and managers;
- Chief Technology Officer;
- Cell technology and manufacturing specialists;
- Clinical and preclinical development specialists.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adimab
  • Bayer
  • Eureka Therapeutics
  • ImmuneXcite
  • Molecular Partners
  • Regeneron Pharmaceuticals
  • MORE
1. Introduction

2. Executive Summary

3. Competitive Landscape Analysis
3.1 Stakeholders
3.1.1 Major biopharmaceutical companies
3.2.2 Small & medium pharmaceutical & biotechnology companies
3.2 Technologies
3.3 Pipeline
3.3.1 Overview
3.3.2 Targets
3.3.3 Competition with other Treatment Modalities
3.3.4 Administration Regimens of T-cell Redirecting Bispecific Antibodies
3.3.5 Next Wave of T-cell and NK-Cell Redirecting Antibodies
3.3.6 Clinical Experience with T-cell and NK-cell redirecting Bispecific Antibodies
3.4 Commercial value of targets, drugs & technologies
3.4.1 Drug prices and sales
3.4.2 Economic terms of collaboration and licensing agreements
3.4.3 Acquisition price (cost) of companies
3.4.4 Public and private financing rounds

4. Company Profiles
4.1 Major Pharma & Biotech
4.1.1 Amgen
4.1.2 AstraZeneca
4.1.3 Bayer
4.1.4 Boehringer Ingelheim
4.1.5 Eli Lilly
4.1.6 GlaxoSmithKline
4.1.7 Janssen Biotech
4.1.8 Pfizer
4.1.9 Roche
4.1.10 Servier
4.2 Small & Medium Pharma & Biotech
4.2.1 Adimab
4.2.2 Affimed Therapeutics
4.2.3 Alligator Biosciences
4.2.4 Ambrx
4.2.5 CytomX
4.2.6 Emergent BioSolutions
4.2.7 EngMab
4.2.8 Eureka Therapeutics
4.2.9 GEMoaB
4.2.10 Generon
4.2.11 Genmab
4.2.12 Glenmark Pharmaceuticals
4.2.13 Immunocore
4.2.14 MacroGenics
4.2.15 Merus
4.2.16 Molecular Partners
4.2.17 Morphosys
4.2.18 Neovii Biotech
4.2.19 OMT Therapeutics
4.2.20 Pieris
4.2.21 Regeneron Pharmaceuticals
4.2.22 Wuhan YZY Biopharma
4.2.23 Xencor
4.2.24 Zymeworks

5. Technology Profiles
5.1 ADAPTIR
5.2 ART-Ig
5.3 Azymetric Scaffold
5.4 BEAT
5.5 Biclonics
5.6 BiTE
5.7 CrossMab
5.8 DART
5.9 Fc-DART
5.10 Dock-and-Lock (DNL)
5.11 DuoBody
5.12 FynomAbs
5.13 ImmTAC
5.14 Knobs-into-Holes
5.15 mAbXcite
5.16 Modified VelocImmune
5.17 TandAb
5.18 T-Cell Engaging Bi-specific (TCB) Probody
5.19 Triomab
5.20 UniDab
5.21 UniTARG/UniMAB
5.22 XmAb Bispecific
5.23 Y-Body Bispecific

6. Drug & Drug Candidate Profiles
6.1 A-337
6.2 AFM11
6.3 AFM13
6.4 AFM21
6.5 AFM22
6.6 AFM24
6.7 AMG 221
6.8 AMG 330
6.9 AMV-564
6.10 BI 836909
6.11 Bispecific anti-CD3-folate
6.12 Blincyto
6.13 CD79b-TDB
6.14 COVA420
6.15 DR5xCD3 DART
6.16 EM801
6.17 EphA2xCD3 DART
6.18 ERY974
6.19 ES414
6.20 ES425
6.21 GBR1302
6.22 GBR1342
6.23 Her2-TDB
6.24 IL13Ra DART
6.25 IMCgp100
6.26 JNJ-63709178
6.27 JNJ-64052781
6.28 M-706
6.29 M-802
6.30 MCLA-117
6.31 MGD006
6.32 MGD007
6.33 MGD009
6.34 MGD014
6.35 Pasotuxizumab
6.36 PF-06671008
6.37 PRS-343
6.38 PSMA-CD3
6.39 REGN1979
6.40 Removab
6.41 RG7802
6.42 RG7828
6.43 ROR1xCD3 DART
6.44 XmAb13551
6.45 XmAb13676
6.46 XmAb14045
6.47 ZW38

7. References

8. Attachment
- Table 16: Clinical Stage T-Cell and NK-Cell Redirecting Bispecific Antibodies
- Table 17: Clinical Combination Studies with T-Cell and NK-Cell Redirecting Bispecific Antibodies
- Table 18: T-Cell and NK-Cell Redirecting Bispecific Antibodies in IND and IND-Enabling Study Phase
- Table 19: T-Cell and NK-Cell Redirecting Bispecific Antibodies in Preclinical R&D

List of Tables

Table 1: Technologies Used by Big Pharma/Biotech in Clinical Stage T-Cell Redirecting Bispecific Antibodies and Compared with Related Technologies
Table 2: T-Cell & NK-Cell Redirecting Bispecific Antibody Technologies from Small & Medium Pharmaceutical Companies and their Licensees
Table 3: Technology Features of Clinical Stage T-Cell & NK-Cell Redirecting Bispecific Antibody Technologies
Table 4: Corporate T-Cell and NK-Cell Redirecting Bispecific Antibody Technologies
Table 5: Targets for T-Cell & NK-Cell Redirecting Bispecific Antibodies
Table 6: Target Competition by Treatment Modalities
Table 7: Technology-Dependent Administration Regimens of Clinical Stage T-Cell & NK-Cell Redirecting Bispecific Antibodies
Table 8: Next Wave of T-Cell and NK-Cell Redirecting Bispecific Antibodies
Table 9: Economic Terms of Licensing Agreements for T-Cell Redirecting Bispecific Antibodies
Table 10: Clinical Development Indications and Status of Blincyto
Table 11: BiTE Development Pipeline by Amgen and/or Partners
Table 12: Affimed’s TandAb Pipeline
Table 13: Goals and Terms of Immunocore’s Partnering Deals for ImmTAC Technology
Table 14: YZY Biopharma‘s Pipeline of T-Cell Redirecting Bispecific Antibodies
Table 15: Clinical Studies with Blincyto (blinatumomab)
Table 16: Clinical Stage T-Cell and NK-Cell Redirecting Bispecific Antibodies
Table 17: Clinical Combination Studies with T-Cell and NK-Cell Redirecting Bispecific Antibodies
Table 18: T-Cell and NK-Cell Redirecting Bispecific Antibodies in IND and IND-Enabling Study Phase
Table 19: T-Cell and NK-Cell Redirecting Bispecific Antibodies in Preclinical R&D
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Adimab
- Affimed Therapeutics
- Alligator Biosciences
- Ambrx
- Amgen
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- CytomX
- Eli Lilly
- Emergent BioSolutions
- EngMab
- Eureka Therapeutics
- GEMoaB
- Generon
- Genmab
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- ImmuneXcite
- Immunocore
- Immunomedics
- Janssen Biotech
- MacroGenics
- Merus
- Molecular Partners
- Morphosys
- Neovii Biotech
- OMT Therapeutics
- Pfizer
- Pieris Pharmaceuticals
- Regeneron Pharmaceuticals
- Roche
- Servier
- Wuhan YZY Biopharma
- Xencor
- Zymeworks
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll